Insomnia - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 99
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I3C9BDC2EBDEN
Leaflet:

Download PDF Leaflet

Insomnia - Pipeline Review, H2 2017
Insomnia - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Insomnia - Pipeline Review, H2 2017, provides an overview of the Insomnia (Central Nervous System) pipeline landscape.

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Insomnia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Insomnia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insomnia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 10, 5, 9, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Insomnia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Insomnia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Insomnia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Insomnia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Insomnia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Insomnia (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Insomnia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Insomnia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Insomnia - Overview
Insomnia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Insomnia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insomnia - Companies Involved in Therapeutics Development
Alexza Pharmaceuticals Inc
Athenex Inc
Eisai Co Ltd
Evotec AG
Grupo Ferrer Internacional SA
Heptares Therapeutics Ltd
Idorsia Ltd
Intec Pharma Ltd
Intra-Cellular Therapies Inc
Johnson & Johnson
Leading BioSciences Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Reviva Pharmaceuticals Inc
Shionogi & Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Yangtze River Pharmaceutical Group
Insomnia - Drug Profiles
(diphenhydramine + lorazepam + zolpidem tartrate) - Drug Profile
ACT-541468 - Drug Profile
CB-2810 - Drug Profile
CY-18 - Drug Profile
CY-20 - Drug Profile
DORA-12 - Drug Profile
DRGT-73 - Drug Profile
Drug for Insomnia - Drug Profile
Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile
EVT-201 - Drug Profile
HTL-6641 - Drug Profile
JNJ-48816274 - Drug Profile
LASSBio-785 - Drug Profile
LASSBio-786 - Drug Profile
lemborexant - Drug Profile
lorediplon - Drug Profile
lumateperone tosylate - Drug Profile
MK-8133 - Drug Profile
MLS-03 - Drug Profile
nebivolol - Drug Profile
NEO-1940 - Drug Profile
piromelatine - Drug Profile
S-117957 - Drug Profile
seltorexant - Drug Profile
Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile
Small Molecules to Activate CYP1A2 for Insomnia and Anxiety - Drug Profile
Small Molecules to Agonize CB1 and CB2 for Autism, Dermatitis and Insomnia - Drug Profile
Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile
TS-142 - Drug Profile
UCM-765 - Drug Profile
zaleplon - Drug Profile
zaleplon - Drug Profile
zolpidem tartrate - Drug Profile
zolpidem tartrate - Drug Profile
Insomnia - Dormant Projects
Insomnia - Discontinued Products
Insomnia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Insomnia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Insomnia - Pipeline by Alexza Pharmaceuticals Inc, H2 2017
Insomnia - Pipeline by Athenex Inc, H2 2017
Insomnia - Pipeline by Eisai Co Ltd, H2 2017
Insomnia - Pipeline by Evotec AG, H2 2017
Insomnia - Pipeline by Grupo Ferrer Internacional SA, H2 2017
Insomnia - Pipeline by Heptares Therapeutics Ltd, H2 2017
Insomnia - Pipeline by Idorsia Ltd, H2 2017
Insomnia - Pipeline by Intec Pharma Ltd, H2 2017
Insomnia - Pipeline by Intra-Cellular Therapies Inc, H2 2017
Insomnia - Pipeline by Johnson & Johnson, H2 2017
Insomnia - Pipeline by Leading BioSciences Inc, H2 2017
Insomnia - Pipeline by Merck & Co Inc, H2 2017
Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
Insomnia - Pipeline by Reviva Pharmaceuticals Inc, H2 2017
Insomnia - Pipeline by Shionogi & Co Ltd, H2 2017
Insomnia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017
Insomnia - Pipeline by Yangtze River Pharmaceutical Group, H2 2017
Insomnia - Dormant Projects, H2 2017
Insomnia - Dormant Projects, H2 2017 (Contd.1), H2 2017
Insomnia - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Insomnia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Alexza Pharmaceuticals Inc
Athenex Inc
Eisai Co Ltd
Evotec AG
Grupo Ferrer Internacional SA
Heptares Therapeutics Ltd
Idorsia Ltd
Intec Pharma Ltd
Intra-Cellular Therapies Inc
Johnson & Johnson
Leading BioSciences Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Reviva Pharmaceuticals Inc
Shionogi & Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Yangtze River Pharmaceutical Group
Skip to top


Ask Your Question

Insomnia - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: